Lobe Sciences Ltd.

Lobe Sciences Ltd.

LOBEF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$9.86M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Lobe Sciences Ltd.Lobe Sciences Ltd.-2.2--274%-0.2
$0.03

Current Fair Value

21.4% downside

Overvalued by 21.4% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$9.86 Million
Enterprise Value$8.69 Million
Earnings per Share$-0.03
Beta0.29
Outstanding Shares277,748,003

Return

Return on Equity-273.72%ROE
Return on Assets-93.31%
Return on Invested Capital-213.66%

Valuation & Multiples

P/E Ratio-2.18P/E Ratio
PEG4.73PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-1.27
Enterprise Value to Net Income-2
Total Debt to Enterprise0.04
Debt to Equity0.18Debt to Equity

Revenue Sources

No data

Next Earnings Call

Expected Date
December 28, 2026
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Lobe Sciences Ltd.

5 employees
CEO: Frederick Dominick Sancilio

Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined...